|  | Pravastatin | Atorvastatin | Timolol | Latanoprost |
---|
Reported effect size* | Change in 5 years | -3.22 | +0.31 | -0.56 | -1.78 |
 | 95% CI limits | (-4.50/-1.93) | (-3.29/+3.91) | (-0.79/-0.34) | (-3.04/-0.51) |
Baselineâ€
| Change in 5 years | -41.80 | -14.63 | -0.70 | -1.82 |
 | 95% CI limits | (-55.74/-27.86) | (-48.38/+19.11) | (-1.08/-0.32) | (-3.69/+0.05) |
Study size‡
| Change in 5 years | +533.54 | +233.63 | +80.55 | -16.94 |
 | 95% CI limits | (-3.94/+1071.01) | (-429.97/+897.23) | (+43.38/+117.71) | (-199.23/+165.35) |
Treatment group§
| Change in 5 years | -0.20 | -0.28 | -0.12 | -0.23 |
 | 95% CI limits | (-0.31/-0.08) | (-0.58/+0.01) | (-0.17/-0.06) | (-0.50/+0.03) |
- Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein cholesterol.
- * Unit of measurement for reported effect size: Change of intraocular pressure measured in mmHg (Timolol, Latanoprost), change in low-density lipoprotein cholesterol measured in % (Pravastatin, Atorvastatin).
-
†Unit of measurement for baseline: Intraocular pressure measured in mmHg (Timolol, Latanoprost), low-density lipoprotein cholesterol measured in mg/dl (Pravastatin, Atorvastatin). To convert low-density lipoprotein cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by 0.0259.
-
‡ Unit of measurement for study size: Number of patients included in final analysis.
-
§ The parameter treatment group has two possibilities: control group = 0, experimental group = 1. Point biserial correlation was used to obtain the equation of the regression line and to calculate the given data.